...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>South African medical journal: Suid-Afrikaanse tydskrif vir geneeskunde >Prevalence of drug-drug interactions of antiretroviral agents in the private health care sector in South Africa.
【24h】

Prevalence of drug-drug interactions of antiretroviral agents in the private health care sector in South Africa.

机译：南非私人保健部门中抗逆转录病毒药物的药物-药物相互作用的流行程度。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVES: Human immunodeficiency virus (HIV) infection can be effectively treated with highly active antiretroviral therapy (HAART), requiring concomitant administration of three to four different agents, often with a high potential for drug-drug interactions (DDIs). This study aimed to determine the prevalence of possible DDIs between antiretrovirals (ARVs) themselves and other drugs. DESIGN: Retrospective drug utilisation study using data from a national medicine claims database for the period 1 January to 31 December 2004. SETTING: A section of the private health care sector in South Africa. SUBJECTS: All ARV prescriptions (N=43 482) claimed during 2004. The possible DDIs found were classified according to a clinical significance rating described by Tatro (2005) in his book Drug Interaction Facts. RESULTS: A total of 5 305 882 medicine items were prescribed; of these, 1.92% (N=101 938) were ARVs. Of the total number of 2 595 254 prescriptions, 1.68% (N=43 482) contained ARVs. A total number of 18 035 DDIs (81 different types) were identified; of these, 83.89% (N=15 130) were DDIs between ARVs and other drugs, while 16.11% (N=2 905) were DDIs between ARVs themselves. Possible DDIs with a clinical significance level of 1 (major, N=17) and 2 (moderate, N=1 436) represented 8.06% (N=1 453) of the total number of identified interactions. CONCLUSIONS: Since concomitant use of ARVs and other drugs used to treat HIV complications is increasing, there is a need to understand and anticipate these DDIs and to overcome them by dose adjustments and patient education, so that they are not life threatening to HIV/AIDS patients.
机译：目的：可以通过高活性抗逆转录病毒疗法（HAART）有效地治疗人免疫缺陷病毒（HIV）感染，需要同时使用三至四种不同的药物，通常具有很高的潜在药物-药物相互作用（DDI）。这项研究旨在确定抗逆转录病毒药物（ARV）本身与其他药物之间可能存在DDI的发生率。设计：回顾性药物利用研究，使用了2004年1月1日至12月31日期间国家药品索赔数据库的数据。地点：南非私人卫生保健部门的一部分。受试者：2004年期间主张的所有ARV处方（N = 43 482）。根据Tatro（2005）在他的《药物相互作用事实》中描述的临床显着性等级对发现的可能的DDI进行了分类。结果：总共开出了5 305 882的药品。其中1.92％（N = 101938）是ARV。在2 595 254张处方中，有1.68％（N = 43 482）包含抗逆转录病毒药物。总共确定了18 035个DDI（81种不同类型）;其中，抗逆转录病毒药物和其他药物之间的DDI为83.89％（N = 15130），而抗逆转录病毒药物本身之间的DDI为16.11％（N = 2905）。临床显着性水平为1（主要，N = 17）和2（中等，N = 1 436）的可能DDI占已鉴定相互作用总数的8.06％（N = 1 453）。结论：由于越来越多地同时使用抗逆转录病毒药物和其他用于治疗HIV并发症的药物，因此有必要了解和预期这些DDI，并通过剂量调整和患者教育加以克服，以免对HIV / AIDS造成生命威胁耐心。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号